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Abstract
A large proportion of medicines used in children are prescribed off-label, and children have often
been denied access to new or innovative medications. Because such situation is unethical, the need
to obtain paediatric information for medicines used in children seems nowadays a matter of
consensus on a global basis. Based on this, it was clear in EU, like what has happened in the US, that
there was a need for a legal obligation for Pharmaceutical Companies to perform studies. This new
European Paediatric Regulation that entered into force in 2007 opens a new era of European drug
regulatory history and will offer a major opportunity to improve children's health through
advancements in research by providing a new framework for evaluating the efficacy and safety of
medicines for children. But, paediatric development remains challenging and the hurdles of
conducting research in paediatric population are numerous. The article presents the new European
Paediatric Regulation, illustrates its rationale through paediatric psychopharmacology, and
discusses some of its consequences on paediatric research from an industry perspective.
Recommendations for further international collaboration are also suggested to make global
paediatric development plans.
Background
A large proportion of medicines used in children are pre-
scribed outside the terms of the drug license i.e. off-label,
which can place children at a direct risk of under- or over-
dosing and a delayed risk of long-term adverse effects.
Many generations of paediatricians and other physicians
have learned to live with the situation [1].
This off-label use of medicines in children has however
been an increasing concern over the last decade leading to
recognize that such situation was unethical as children
have not access to medications properly assessed.
US perspective
In 1994, the United States implemented the "Pediatric
Labeling Rule" which paved the way for legislation aimed
at producing drugs for children. But the first critical paedi-
atric legislative initiative in the US is the Food and Drug
Administration Modernization Act that in 1997 provided
an incentive for Pharmaceutical Companies to study
products for which there would be a health benefit in the
paediatric population. This legislation enacted a volun-
tary process where FDA would define the products which
needed paediatric studies, outline the necessary studies,
and issue sponsors a Paediatric Written Request (PWR). If
the Pharmaceutical Companies submitted studies
responding to the PWR, six additional months of market-
ing exclusivity were received. This process has been the
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main legislative initiative that has moved paediatric drug
development in the US. However some gaps were identi-
fied in the FDA's 2001 Report to Congress, e.g. that this
incentive legislation was only working for some products,
and were partially addressed by the Best Pharmaceuticals
for Children in 2002 (BPCA). This Act renewed the exclu-
sivity incentives, created an off-patent process involving
government contracts for paediatric studies, and man-
dated public disclosure of the study results. In 1997, the
FDA proposed, and in 1998 finalized the Pediatric Rule.
In December 2003, the Pediatric Research Equity Act
(PREA) was enacted, putting into legislation most compo-
nents of the Pediatric Rule for instance requiring paediat-
ric assessment for certain applications unless waived or
deferred.
These critical steps taken in the late 1990's and early
2000's in the US were amended and reauthorized in 2007
as Pediatric Research Equity Act of 2007 and Best Pharma-
ceuticals for Children Act of 2007. Both of these are clearly
designed to encourage more paediatric research and more
development of paediatric medicines.
EU perspective
In 2000 in the European Union, fifty per cent or more of
medicines used in children have never been studied in this
population, but only in adults, and not necessarily in the
same indication (or the same disease) [2]. Even if paediat-
ric clinical studies have been performed in some cases,
very few medicinal products used have a paediatric indica-
tion and a defined posology, and even less a formulation
allowing the administration to young children.
The need for more studies to obtain paediatric informa-
tion for medicines used in children seems nowadays a
matter of consensus on a global basis [3]. Based on this, it
was clear in EU that there was a need for a legal obligation
for Pharmaceutical Companies to perform studies if they
intended to develop medicines for use in the paediatric
population [3].
The New European Paediatric Legislation
A new legislation governing the development and author-
isation of medicines for paediatric use (children and ado-
lescents aged 0 to 17 years) was introduced in the
European Union (EU) in December 2006 and entered
into force in January 2007 [4]. Like the US paediatric leg-
islation, the goals of the EU legislation are the same i.e. to
improve children's health through advancements in
research and to provide a new framework for evaluating
the efficacy and safety of medicines for children. However,
unlike in the US, the EU legislation is leading to more pro-
found and faster changes in the field of paediatric devel-
opment in Europe; more profound as unlike in the US
paediatric development will become mandatory in EU for
all new medicinal products in development unless a
waiver is granted, and as Pharmaceutical Companies have
to send a paediatric investigation or development plan as
early as the end of pharmacokinetic studies in adults;
faster as the changes are occurring in EU in a shorter
period of time. Actually, the timelines of obligation for
Pharmaceutical Companies are that: 18 months from
entry into force (July 2008), applications for new market-
ing authorisation applications (new products) should
contain results of studies conducted in compliance with
agreed Paediatric Investigation Plan (PIP) unless waiver or
deferral; 24 months from entry into force (January 2009),
application for new indications, new routes of administra-
tion or new pharmaceutical forms should contain results
of studies in compliance with agreed PIP unless waiver or
deferral.
The aim of this new regulation is to improve the health of
the children of Europe, by:
- Increasing high quality research into medicines for them,
- Promoting the development and authorisation of such
medicines, and over time, ensuring that the majority of
medicines used by children are specifically authorized for
such use,
- Improving the availability of high quality information
on medicines designed for children.
This regulation makes paediatric development as an obli-
gation in the EU, with the following key points:
- Creation of a European Paediatric Committee (PDCO),
replacing the former Paediatric Expert Group. The PDCO
first met in July 2007. The committee is composed of
experts with competence in the development and assess-
ment of all aspects of paediatric medicinal products and
the EMEA Executive Director must ensure that the final
composition of the PDCO covers all related relevant dis-
ciplines: 5 members (and alternates) from the Committee
for Medicinal Products for Human Use (CHMP), 1 mem-
ber (and alternates) from each Member State not repre-
sented via CHMP membership, 6 members (and
alternates) appointed by the European Commission rep-
resenting healthcare professionals (3) and patients' organ-
isations (3). The PDCO has been operational with 27
members, even before finalisation of the appointment by
the European Commission of the further 6 members rep-
resenting healthcare professionals and patients' associa-
tions.
- Submission of Paediatric Investigation Plan (PIP) at
availability of adult pharmacokinetic studies, i.e. at an
early phase of the development of a new compound. AChild and Adolescent Psychiatry and Mental Health 2008, 2:38 http://www.capmh.com/content/2/1/38
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PIP is a development plan aimed at ensuring that the nec-
essary data are obtained through studies in children, when
it is safe to do so, to support the authorisation of the med-
icine for children. The plan should be submitted by Phar-
maceutical Companies to the PDCO Committee, which is
responsible for agreement or refusal of the plan.
- Paediatric data is mandatory for all regulatory submis-
sions for new products and for products still on patent in
case of line extension (unless waivers or deferrals) accord-
ing to a PIP agreed upon by the PDCO.
- PIP reflects the development plan on clinical, non-clini-
cal and technical aspects including timelines and covers
all existing or planned (adult) indications and dosage
forms (including specific age-appropriate paediatric for-
mulation or route of administration if necessary). Appli-
cations should also cover all subsets (according to ICH
E11) of the paediatric population from birth to adoles-
cence. The plan clearly defines the timing of studies in
children compared to adults. In some cases, studies will
be deferred until after the studies in adults have been con-
ducted, to ensure that research with children is done only
when it is safe and ethical to do so.
- PIP can be amended and is binding on the company.
- Reward for studies conducted can result in a 6-month
patent extension.
This should be achieved without subjecting children to
unnecessary clinical trials and should not delay the
authorisation of medicines for use in adults.
In certain circumstances, the requirement to submit a pae-
diatric investigation plan can be waived for specific
medicinal products or classes of medicinal products that:
- Are likely to be ineffective or unsafe in part or all of the
paediatric population,
- Are intended for conditions that occur only in adult pop-
ulations e.g. Alzheimer's disease,
- Do not represent a significant therapeutic benefit over
existing treatments for paediatric patients.
In accordance with the Paediatric Regulation, the PDCO
has adopted a list of conditions that occur only in adult
populations. All classes of medicinal products intended to
treat these conditions will therefore be exempt from the
requirement for a paediatric investigation plan.
Discussion
The example of child psychopharmacology
If the therapeutic effects of amphetamines in hyperactive
children were first described in 1937, thus, preceding the
major discoveries of adult psychopharmacology, since
this, little innovation has occurred in paediatric psychop-
harmacology [5]. Furthermore, while progress in the rec-
ognition and treatment of mental disorders in childhood
and adolescence has been accomplished, the task of turn-
ing basic research findings into clinically useful applica-
tions still remains in front of us [6].
Actually, only few psychotropic medications are approved
for use in the paediatric population. However, it has
become increasingly common to use these medications to
treat a variety of mental health disorders in children and
adolescents but this has not constantly been supported by
rigorous scientific data. A study of the prescribing trends
in nine countries between the years 2000 and 2002, evi-
denced that the increase in psychotropic prescribing in
children was not only confined in the USA and UK but is
also evident in the 7 other examined countries (Argentina,
Brazil, Canada, France, Germany, Mexico & Spain) [7].
The questions related to the use of Selective Serotonin
Reuptake Inhibitors (SSRIs) in Paediatric Major Depres-
sive Disorder (MDD) can provide an opportunistic exam-
ple of where paediatric pharmaceutical research can
improve. The official recognition of depression in chil-
dren and adolescents in Europe took place in 1971, when
the Union of European Pedopsychiatrists recognised and
addressed the needs of depressed children and adoles-
cents by declaring that depression is an important illness
that constitutes a significant proportion of mental disor-
ders in children and adolescents [8]. During the 1980s,
the arrival of the SSRIs, which resulted in far less side
effects than tricyclics or monoamine oxidase inhibitors,
was viewed as an important step in the treatment of affec-
tive disorders, first in adults and then in children and ado-
lescents [9]. Simultaneously, the literature on the
treatment of MDD in children and adolescents has signif-
icantly grown since the introduction of the SSRIs.
Although the exact mechanism of action responsible for
the therapeutic effects of many psychotropics remains
unknown, the basic biochemical activity of these medica-
tions is generally considered to be similar across all ages
[10]. In both paediatric and adult patients, SSRIs block the
reuptake of serotonin and their antidepressant effect has
been found to be associated with the degree of inhibition
of the serotonin transporter in platelets [11]. However, it
still remains to be proven whether SSRIs that are effica-
cious in adults are also efficacious in treating MDD in
children and adolescents [12]. Most of the clinical studies
did not demonstrate superiority of active treatment when
compared to placebo as: only fluoxetine was repetitivelyChild and Adolescent Psychiatry and Mental Health 2008, 2:38 http://www.capmh.com/content/2/1/38
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superior to placebo on primary outcome measures; stud-
ies of citalopram, sertraline and escitalopram recently
[13], have also shown superiority over placebo on pri-
mary outcome measures; studies of paroxetine, venlafax-
ine, mirtazapine, nefazodone, and tricyclics, have not
demonstrated superiority of any of these pharmacological
treatments over placebo on the primary efficacy measures
[9,14-16]. At present, only fluoxetine is approved in EU
and US for paediatric MDD.
The reasons why many of these studies have failed
remains unclear. Although some of these antidepressants
may not be beneficial (like probably tricyclics), methodo-
logical considerations have been raised, among them dos-
ing issues should be carefully evaluated. Extrapolation
from adult data is definitively insufficient. Some authors
hypothesized that inaccurate dosing parameters may have
participated in the negative outcome of the studies of anti-
depressants in paediatric patients with MDD [17].
Key parameters of dosing that should be evaluated
include identifying an appropriate total daily dose and
determining how frequently the medication needs to be
administered every day. If a medication is not dosed prop-
erly, clinical efficacy might no be detected during a clinical
trial [17]. The selection of doses in paediatric patients
requires a consideration of pharmacokinetic parameters
and warrants specific studies in children and adolescents
to establish benefits and risks during drug development
[18], deemed as a pivotal aspect of paediatric drug devel-
opment. Reviewing the pharmacokinetic (PK) studies per-
formed in children and adolescents with SSRIs, R.
Findling et al. in 2006 concluded that in many instances,
the dosing strategies that have been employed in the pla-
cebo-controlled efficacy studies in juvenile MDD were not
supported by the data available from PK studies [17].
Therefore, these authors emphasize the need to develop
evidence-based dosing strategies before studying any drug
in paediatric population as medication dosing regimens
may have contributed to both failure to demonstrate effi-
cacy and safety and tolerability concerns [17]. Reviewing
the paediatric randomized controlled MDD trials,
Moreno et al. reached a similar conclusion: as antidepres-
sants have two to three times shorter half-lives in young-
sters, they need to be administered more often than to
adults to avoid withdrawal symptoms between doses that
can be wrongly interpreted as the absence of an adequate
response with the exception of fluoxetine, which has a
longer half-life [12]. Consequently PK and dose ranging
studies are needed to inform the design of definitive effi-
cacy trials. But such type of paediatric studies remain dif-
ficult to perform and alternative like modeling are
developed as they are ethically challenging mainly due to
the fact that such research does not offer a prospect of
direct benefit.
The new EU Paediatric Regulation: an ongoing learning 
process
Contrary to what has happened in the US, the EU paedi-
atric legislation is leading to more dramatic and faster
changes in a still moving and complex environment. The
legislation entered into force in January 2007, the PDCO
first met in July 2007, and the Commission Guideline on
format and content of Paediatric Investigation Plan was
on a draft format until September 2008 when the final
version was published by the European Commission,
implying that all stakeholders had and still will have to
work together and interact to overcome the challenges of
this new regulation.
Numerous aspects of this new process will lead to interest-
ing interactions and future developments.
The EU paediatric legislation does not make any differ-
ence between products already on the market and drugs in
development. The transition period does not allow
enough flexibility to take into account in some cases, spe-
cific product patent timelines meaning that paediatric
development may not be possible for some products still
on patent. It is too early to draw any clear conclusion but
the fact that after one year almost two third of the applica-
tions are for medicines that are not yet authorised or
approved in EU (PDCO first anniversary) seems to be in
favour of this concern. It could be wished that for new
products, there would be more opportunities to interact
with the PDCO. Therefore, it could be of interest to offer
further opportunities of direct interactions between the
PDCO and the Pharmaceutical Companies as improving
the communication around the common goal to develop
better medicines for children between the PDCO and the
Pharmaceutical Companies can only be beneficial.
Towards a new drug development paradigm?
It is too early to determine how the new EU paediatric reg-
ulation will affect the way in which drugs are developed.
For Pharmaceutical Companies, the requirements result-
ing from the paediatric regulation would probably lead to
a new drug development paradigm integrating paediatric
considerations extremely early in the process of develop-
ing a new chemical entity.
If the timing of PIP submission i.e. the end of adult PK
studies can be interpretated as favouring such paradigm,
more emphasis on integrated paediatric and adult devel-
opment could have been suggested in the Commission
Guideline. Such new drug development paradigm how-
ever will pose specific ethical and scientific challenges.
The example of atomoxetine development can be useful,
as it has heavily been influenced by US paediatric regula-
tion and guidance from the FDA, also showing that newChild and Adolescent Psychiatry and Mental Health 2008, 2:38 http://www.capmh.com/content/2/1/38
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and integrated adult and paediatric models can be
achieved [19].
Need for a review of EMEA guidelines for paediatric 
considerations
The EMEA guidelines for psychiatric conditions (mainly
for efficacy) will need to be revised with specific paediatric
considerations. These guidelines provide already some
clear guidance as they confirm the existence of numerous
paediatric conditions in different age groups (according to
ICH E 11 [20]) but the methodological sections lack pae-
diatric specificities. The first paediatric EMEA guideline
under development will be for ADHD and should offer an
integrated adult/paediatric development.
Two specific aspects can illustrate this question such the
use of placebo in children and adolescents and the ques-
tion of comorbidity.
If from a scientific point of view, randomised double-
blind comparisons versus placebo are often preferable to
permit adequate evaluation of efficacy and safety/tolera-
bility, the use of placebo raises ethical concerns poten-
tially leading to different opinions between Health
Authorities and Ethics Committees. Ethical requirements
must be taken into consideration when designing paediat-
ric protocols and PIPs and paediatric protocols cannot
simply be mimic adult protocols. For instance, rescue
treatment and escape procedures should always be con-
sidered in paediatric trials: rescue refers to treatment that
may be given on top of trial medications to avoid danger
or distress, for example pain treatment, as soon as the
patient reaches a defined level; escape refers to prompt
removal of subjects whose clinical status worsens or fails
to improve to a defined level in a trial [21].
Comorbidity is not accepted in the current EMEA guide-
lines, and the patients to be included in the trials should
have only one specific disease (e.g. patients with MDD
and with no anxiety disorders). However, it is well estab-
lished in child and adolescent psychiatry that comorbidity
is the rule rather than the exception [22]: clinical and epi-
demiological investigations have revealed that 40%–70%
of depressed children and adolescents have comorbid psy-
chiatric disorders and that at least 20%–50% have two or
more comorbid diagnoses [8].
Limited EU paediatric experience
Compared to the US, the EU experience in paediatric
research is less extensive. In the field of child and adoles-
cent psychopharmacology, the majority of publications
and studies are coming from the US. Reviewing 27 pla-
cebo-controlled trials assessing the use of antidepressant
medications among more than 4400 children and adoles-
cents published between January 1998 and July 2006 in
Medline, Apter et al. reported that 23 out of 27 were con-
ducted solely in the US and only 3 were done partly in
European countries [23]. This new legislation will help
developing an EU network of potential investigators in
child and adolescent psychiatry, emphasizing that identi-
fication and training of new research centers will also have
to take place. However it will be necessary to take into
account the public perception of paediatric research in
Europe and the awareness of Ethics Committees. Cur-
rently, the European Commission's Guideline on the PIP
does not take into account feasibility issues. If this is
understandable, such feasibility potential issues or con-
cerns will be translated to facts e.g. geographic localisation
of the study when the first studies part of the PIPs will be
recruiting and may lead to PIPs amendments.
Towards a global paediatric development plan
Another major challenge will be to ensure as much as pos-
sible global paediatric development mainly for EU and US
(keeping however in mind that other countries are also
following this path of paediatric legislation), working ide-
ally on common study designs in order to avoid unneces-
sary duplication of studies and expose children to undue
risks. In June 2007, the US Food and Drug Administration
(FDA), the European Commission (EC), and the Euro-
pean Medicines Agency (EMEA) have agreed to expand
their current cooperative activities in several important
areas including paediatrics. Numerous scientific issues
offer an opportunity to seek a consensus between EU and
US like for instance recommendations concerning the use
of placebo or active comparators in paediatric psychop-
harmacology. At present, the FDA and the EMEA already
work together, having monthly teleconferences, exchang-
ing information on paediatric development. Both the
EMEA and FDA are committed to develop a framework:
- To facilitate regular exchange of scientific and ethical
issues and other information on paediatric development
programmes in Europe and the US to avoid exposing chil-
dren to unnecessary trials.
- To aim at global paediatric development plans based on
scientific grounds and compatible for both Agencies.
However as the current different legal/regulatory require-
ments may prevent receiving identical applications for
paediatric development plans, it would be of paramount
importance to explore new areas of transatlantic regula-
tory cooperation and further strengthen such collabora-
tion by developing a common process between FDA and
EMEA, aiming for a global paediatric plan. A possible start
towards global paediatric development could be to make
Pediatric Written Requests and Paediatric Investigation
Plans compatible; for instance considering the possibility
of potentially amending the PWR or PIP depending on theChild and Adolescent Psychiatry and Mental Health 2008, 2:38 http://www.capmh.com/content/2/1/38
Page 6 of 7
(page number not for citation purposes)
feedback or requests of the other Agency and even incor-
porating such possibility in both regulations could offer
an opportunity to make paediatric research more effective.
Financial aspect of paediatric development
Finally, the financial aspect of paediatric development
cannot be eluded and its impact on Pharmaceutical Com-
panies will have to be assessed. In 2007, before the US
paediatric legislation was renewed, Li et al [24] examined
the returns on investment of completing paediatric exclu-
sivity and demonstrated that the distribution of net eco-
nomic return for 6 months of exclusivity varied
substantially among products, being very positive for
blockbusters but being also potentially negative in some
cases. They concluded that the Pediatric Exclusivity Pro-
gram overcompensates blockbuster products for perform-
ing clinical trials in children. There is a concern that, if
paediatric development is more difficult and expensive
than anticipated, about what could be the potential risk
on research in Europe for primarily EU companies, espe-
cially for small or medium size companies.
Conclusion
The European Paediatric Regulation is a major achieve-
ment and opens a new era of European drug regulatory
history. Children have often been denied access to new or
innovative medications and paediatric development still
depends on the outcome of the adult development. This
Regulation offers a major opportunity to improve chil-
dren's health. But, paediatric development remains chal-
lenging and the hurdles of conducting research in
paediatric population are numerous including 'moral'
and ethical issues, scientific issues, practical issues and
finally financial issues. Therefore as a shared responsibil-
ity among companies, regulatory authorities, health pro-
fessionals, and society as a whole (ICH E-11), it is through
the lessons learned during the implementation of this
new legislation and the numerous dialogues that will
result, that changes will occur, promoting paediatric
research. Clearly further regulatory and scientific interna-
tional collaborations are warranted to favour global pae-
diatric development plans in order to federate efforts and
initiatives, and consequently make paediatric research
more effective and efficient. Ultimately, it is through well-
conducted ethical and quality research that children and
adolescents will gain access to new medications and
receive safe and optimal drug therapy.
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